Nausea and vomiting in pregnancy (NVP) affects as many as 80 percent of pregnant women. Although often referred to as morning sickness, symptoms can occur throughout the day and range from mild nausea to persistent vomiting, dehydration, weight loss and, in its most severe form, hyperemesis gravidarum. Despite its prevalence, only an estimated 10 to 20 percent of women experiencing NVP use conventional anti-nausea medications. Researchers say this low treatment rate may reflect concerns about medicine safety during pregnancy, limited access to subsidised therapies and the tendency of some patients and clinicians to tolerate significant symptoms rather than navigate a restrictive pharmaceutical system.

The study, published in Acta Obstetricia et Gynecologica Scandinavica, examined PBS dispensing records associated with almost 300,000 pregnancies over a five-year period. The researchers compared medication use and public expenditure across regions with different socioeconomic profiles. Their aim was not simply to measure how much the government spent, but to determine whether the design of the subsidy system influenced which antiemetic medicines women could obtain. The results indicate that the PBS does provide important financial protection, but that its narrow range of pregnancy-relevant options may also produce unequal patterns of access.

One of the clearest findings involved ondansetron, a medicine widely used to control nausea and vomiting. Although ondansetron does not have a specific pregnancy indication or dedicated PBS listing for NVP, it accounted for 54 percent of total PBS expenditure on anti-nausea medicines dispensed during pregnancy. Its use increased more rapidly in lower-income areas, suggesting that doctors may have been relying on subsidised pathways to make the medicine affordable for patients who could not pay the full cost themselves. In Australia, prescribing a drug “off-label” means using it for a condition, patient group or stage of life not explicitly covered by its formal regulatory approval. Off-label prescribing is legal and common in medicine, particularly in pregnancy, but it can involve limited evidence, additional clinical responsibility and inconsistent access.

The researchers describe this pattern as a kind of “Robin Hood” effect. Clinicians appear to be using available system mechanisms to help financially vulnerable patients obtain medicines they believe are clinically necessary. Such prescribing may also reduce pressure on hospitals if effective treatment prevents dehydration, malnutrition or complications that would otherwise require emergency care or inpatient management. However, the workaround is not an equitable substitute for a clearly regulated and properly subsidised treatment framework. It can depend on individual prescribers’ knowledge, willingness to prescribe outside usual restrictions and ability to navigate administrative rules.

The roots of this cautious regulatory environment extend back decades. The thalidomide tragedy, in which a medication prescribed to pregnant women caused severe birth defects, transformed drug regulation and permanently influenced how medicines are evaluated for use during pregnancy. Because pregnant people are often excluded from clinical trials, evidence about the safety and effectiveness of many medicines can remain incomplete. Regulators and pharmaceutical companies may also be reluctant to invest in pregnancy-specific studies, particularly when the potential legal and ethical risks are high. The result is a paradox: pregnancy is a period when medication decisions are especially important, yet high-quality evidence can be more limited than it is for other patient populations.

The study’s findings suggest that this evidence gap is reinforced by the structure of the PBS. Women on lower incomes may be restricted largely to older medicines that are subsidised, even when clinicians consider newer or repurposed treatments more appropriate for a particular patient. Women with greater financial capacity, by contrast, may be able to purchase non-PBS medicines privately, allowing them to access a wider selection of guideline-recommended therapies. In practice, two patients with similar symptoms may therefore receive different treatment options because of their ability to pay rather than differences in disease severity.

The researchers argue that this disparity represents both a public health and policy problem. When clinicians prescribe outside formal PBS restrictions to ensure that vulnerable patients receive treatment, the system may be spending public money in ways that are less transparent and less strategically planned. At the same time, women who cannot afford private prescriptions may experience prolonged vomiting, missed work, reduced nutrition and avoidable hospital visits. Associate Professor Luke Grzeskowiak of Flinders University said that the current arrangement allows disadvantaged women to rely on a narrow set of subsidised medicines while wealthier patients can self-fund the full range of options.

The authors are calling for Australia’s medication funding structures to be updated, particularly as maternal health has been identified as a national priority. They recommend expanding the range of medicines evaluated and subsidised for pregnancy-related conditions, including both newer drugs and existing medicines that could be repurposed on the basis of emerging evidence. Dr Hannah Jackson, the study’s lead author and a recent PhD graduate from UTS, said reform could create a more dynamic, evidence-based system that responds to the real treatment needs of pregnant women. Without change, the researchers warn, Australia may continue to see socioeconomic inequality, widespread off-label prescribing and potentially inefficient public spending built into the management of one of pregnancy’s most common medical problems.

Subject of Research: People

Article Title: Pharmaceutical policy and off-label prescribing in pregnancy: A population-based historical cohort study analyzing inequality in access to antiemetics within Australia’s Pharmaceutical Benefits Scheme

News Publication Date: 11 June 2026

Web References: https://doi.org/10.1111/aogs.70283

References: Acta Obstetricia et Gynecologica Scandinavica, DOI: 10.1111/aogs.70283

Keywords: pregnancy, morning sickness, nausea and vomiting in pregnancy, antiemetics, ondansetron, Pharmaceutical Benefits Scheme, PBS, off-label prescribing, maternal health, health inequality, Australia, pharmaceutical policy

Hyperemesis gravidarum is much more than common morning sickness; it is a severe form of nausea and vomiting during pregnancy that can result in serious health complications for both mother and fetus. The condition affects approximately 1 to 3 percent of pregnant individuals and, if left unmanaged, can lead to dehydration, electrolyte imbalances, and nutritional deficiencies. This study illustrates how understanding the nuances of hyperemesis gravidarum can lead to improved interventions and better health outcomes for affected women.

At the heart of the research lies a policy lab aimed at harnessing collective expertise from different sectors to devise actionable strategies. This collaborative effort is essential, as hyperemesis gravidarum often requires a coordinated approach involving healthcare providers, patients, researchers, and policymakers. By bringing these stakeholders together, the lab seeks to create innovative solutions that are grounded in real-world experiences and scientific evidence.

One of the innovative strategies outlined in the research involves the integration of technology into patient care. The researchers advocate for the development of digital platforms that empower women to track their symptoms and receive timely interventions. Such platforms could facilitate continuous communication between patients and practitioners, ensuring that women receive the support they need when they need it most. This modern approach not only enhances patient engagement but also informs providers of the most effective methods for managing symptoms.

Furthermore, the study emphasizes the importance of training healthcare providers to recognize and address hyperemesis gravidarum swiftly. Education is a crucial component; inadequate awareness among practitioners can lead to misdiagnosis or inadequate treatment. By implementing training programs that raise awareness about the condition’s severity and promote evidence-based practices, the research team posits that healthcare quality can be significantly improved.

Additionally, addressing the psychological aspects of hyperemesis gravidarum is paramount. Women suffering from this condition often experience not only physical distress but also emotional turmoil. The policy lab recognizes the importance of mental health services integrated with pregnancy care, ensuring that women receive holistic support. Research shows that when emotional and mental health concerns are addressed simultaneously with physical symptoms, recovery and overall well-being improve.

The researchers also delve into the healthcare system’s role in facilitating access to necessary treatments and resources. Barriers such as cost, availability of medication, and access to specialized care can exacerbate the already challenging experience of hyperemesis gravidarum. Therefore, the proposed strategies also focus on policy reform that champions equitable access to care for all women, regardless of socioeconomic status.

In the quest for solutions, the research team encourages the utilization of data to inform policy decisions. By systematically collecting and analyzing data related to hyperemesis gravidarum, health authorities can better understand the implications of the condition on public health. This evidence base can drive legislation and funding towards interventions that matter most, ultimately improving the quality of care for all pregnant individuals.

Additionally, community engagement is highlighted as a critical element of the policy lab’s efforts. Involving local organizations and support networks can lead to the dissemination of information and resources tailored to specific populations. This grassroots approach allows for a more nuanced understanding of how hyperemesis gravidarum uniquely affects different communities and fosters resilience among those impacted by the condition.

Moreover, the research underscores the need for enhanced research funding specifically targeted at hyperemesis gravidarum. Historical underfunding has left significant gaps in knowledge regarding the condition’s causes, risk factors, and long-term effects on mothers and their children. By advocating for increased investment in research, the policy lab aims to bolster the scientific community’s capacity to uncover vital information that can drive future interventions.

The collaboration extends beyond the research lab, seeking to create partnerships with advocacy groups and organizations devoted to women’s health. This coalition aims to amplify voices and drive broader societal change concerning reproductive health issues. As public awareness grows, it becomes increasingly important for these advocacy efforts to intersect with policy development to create comprehensive solutions.

In conclusion, the research conducted by Nana, Haggar, Boulding, and their team represents a potential turning point in how hyperemesis gravidarum is perceived and managed. By leveraging a multifaceted approach that includes technological innovation, education, mental health support, and policy reform, the project sets the stage for a more effective management strategy that can significantly improve outcomes for women facing this challenging condition. This work is vital not only for the individual but also for the advancement of women’s health as a whole, paving the way for a future where conditions such as hyperemesis gravidarum receive the attention and resources they rightly deserve.

The findings of this study are a clarion call to all stakeholders involved in health care, highlighting that effective management of hyperemesis gravidarum requires collaboration, innovation, and a commitment to patient-centered care. As the discourse surrounding women’s health continues to evolve, the insights gleaned from this research will undoubtedly serve as a guiding framework for future studies and policy developments.

Subject of Research: Hyperemesis Gravidarum Management

Article Title: Advancing the women’s health strategy: a policy lab aimed at improving effective management of hyperemesis gravidarum

Article References:

Nana, M., Haggar, T., Boulding, H. et al. Advancing the women’s health strategy: a policy lab aimed at improving effective management of hyperemesis gravidarum.
Health Res Policy Sys 23, 123 (2025). https://doi.org/10.1186/s12961-025-01384-y

Image Credits: AI Generated

DOI: 10.1186/s12961-025-01384-y

Keywords: Hyperemesis Gravidarum, Women’s Health, Policy Lab, Health Strategy, Prenatal Care, Treatment Innovation, Healthcare Access